Policy & Regulation
Fujifilm reports Avigan effective in Phase-3 trial for treatment of COVID-19 patients
23 September 2020 -

Fujifilm Holdings Corp (Fujifilm) (TYO:4901) said on 23 September 2020 that a late-stage study of its antiviral drug Avigan showed it reduced recovery times for COVID-19 patients with non-severe symptoms, boosting expectations for regulatory approval in Japan, Reuters news agency reported on Wednesday.

In a release, the company said that the Phase 3 clinical study of 156 patients in Japan showed that those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group. Also, results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were statistically significant.

In its statement, Fujifilm said it would perform further analysis of the trial data and seek to file for approval of Avigan for use in COVID-19 as early as October 2020.

In July 2020, Fujifilm had sold its global rights to Avigan to India's Dr Reddy's Laboratories. Already available generically in many countries under the name favipiravir, the drug has been approved to treat COVID-19 in India and Russia.



Related Headlines